Kyushu Communication: Betamethasone Sodium Phosphate Injection Obtains Drug Registration Certificate.

Kyushu Tong Announcement, June 4, 2025, Huiyu Yuanhe Pharmaceuticals Co., Ltd., a subsidiary of the wholly-owned subsidiary Jingfeng Pharmaceuticals, received the "Drug Registration Certificate" for betamethasone sodium phosphate injection issued by the State Food and Drug Administration. This drug is a glucocorticoid drug with anti-inflammatory, immunosuppressive, and anti-allergy effects, and can be clinically used to treat a variety of inflammatory diseases. In 2023, sales of betamethasone sodium phosphate injection in public medical institutions in China exceeded 220 million yuan, making it one of the top 8 corticosteroid products for systemic use. The approval of this drug will help expand market share, further enrich the company's injection product pipeline, and enhance the company's competitiveness in the injection product market.